GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guard Therapeutics International AB (OSTO:GUARD) » Definitions » EV-to-EBIT

Guard Therapeutics International AB (OSTO:GUARD) EV-to-EBIT : -3.26 (As of Jun. 02, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Guard Therapeutics International AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Guard Therapeutics International AB's Enterprise Value is kr312.87 Mil. Guard Therapeutics International AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-95.88 Mil. Therefore, Guard Therapeutics International AB's EV-to-EBIT for today is -3.26.

The historical rank and industry rank for Guard Therapeutics International AB's EV-to-EBIT or its related term are showing as below:

OSTO:GUARD' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.21   Med: 0.89   Max: 1.11
Current: -3.26

During the past 13 years, the highest EV-to-EBIT of Guard Therapeutics International AB was 1.11. The lowest was -17.21. And the median was 0.89.

OSTO:GUARD's EV-to-EBIT is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 8.875 vs OSTO:GUARD: -3.26

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Guard Therapeutics International AB's Enterprise Value for the quarter that ended in Dec. 2024 was kr183.11 Mil. Guard Therapeutics International AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-95.88 Mil. Guard Therapeutics International AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -52.36%.


Guard Therapeutics International AB EV-to-EBIT Historical Data

The historical data trend for Guard Therapeutics International AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guard Therapeutics International AB EV-to-EBIT Chart

Guard Therapeutics International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.64 -3.21 -1.77 -2.44 -1.91

Guard Therapeutics International AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.44 -1.41 -3.25 -3.18 -1.91

Competitive Comparison of Guard Therapeutics International AB's EV-to-EBIT

For the Biotechnology subindustry, Guard Therapeutics International AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guard Therapeutics International AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guard Therapeutics International AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Guard Therapeutics International AB's EV-to-EBIT falls into.


;
;

Guard Therapeutics International AB EV-to-EBIT Calculation

Guard Therapeutics International AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=312.865/-95.881
=-3.26

Guard Therapeutics International AB's current Enterprise Value is kr312.87 Mil.
Guard Therapeutics International AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-95.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guard Therapeutics International AB  (OSTO:GUARD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Guard Therapeutics International AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-95.881/183.112722137
=-52.36 %

Guard Therapeutics International AB's Enterprise Value for the quarter that ended in Dec. 2024 was kr183.11 Mil.
Guard Therapeutics International AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-95.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guard Therapeutics International AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Guard Therapeutics International AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Guard Therapeutics International AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 22, Lund, SWE, 223 63
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.

Guard Therapeutics International AB Headlines

No Headlines